A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models ...

Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust ...

A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, ...

What happened at BIO? This selected coverage from the BIO 2026 meeting in San Francisco includes highlights from panels on ...

The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion's (OPDP’s) 2026 untitled letters do more than identify a handful of promotional missteps. Read together with the agency’s ...

Achieving regulatory approval for a new drug is an extraordinary achievement. The bar for success is high. Many companies with breakthrough scientific discoveries and promising clinical data still ...

Biotech has entered a new era of financial discipline. The days of easy capital, billion-dollar preclinical valuations, and “platform first, data later” investing have largely disappeared. Today, ...

Emerging biotech companies are tasked with a dual mandate: advance breakthrough science to create new medicines for patients, and in doing so, create value for investors. There is no established ...

GLP-1s didn’t just change how patients lose weight. They changed how pharma must sell. GLP-1 receptor agonists were supposed to be a diabetes treatment. Instead, they became the first pharmaceutical ...

Drug and device manufacturers have long sought clearer rules for sharing scientific information about unapproved (off-label) uses of their products with health care providers (“HCPs”). In January 2025 ...

The era of outsourced regulatory work and rented thinking is ending. Agentic AI makes in-house capability inevitable, if leadership has the nerve to build it. Every biopharma CEO now claims to run an ...

For much of the past two decades, the geography of pharmaceutical innovation was relatively stable. Discovery and capital clustered in hubs such as Boston, San Diego, and Basel. Asia played an ...